Mapping SARS-CoV-2 antigenic relationships and serological responses-Reference-Cited by-同舟云学术

Mapping SARS-CoV-2 antigenic relationships and serological responses

Published:2023-10-06 Issue:6666 Volume:382 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Wilks Samuel H.¹^ORCID,Mühlemann Barbara²³^ORCID,Shen Xiaoying⁴⁵^ORCID,Türeli Sina¹,LeGresley Eric B.¹^ORCID,Netzl Antonia¹^ORCID,Caniza Miguela A.⁶^ORCID,Chacaltana-Huarcaya Jesus N.⁷^ORCID,Corman Victor M.²³^ORCID,Daniell Xiaoju⁴^ORCID,Datto Michael B.⁸^ORCID,Dawood Fatimah S.⁹,Denny Thomas N.⁵,Drosten Christian²³^ORCID,Fouchier Ron A. M.¹⁰^ORCID,Garcia Patricia J.¹¹^ORCID,Halfmann Peter J.¹²^ORCID,Jassem Agatha¹³,Jeworowski Lara M.²^ORCID,Jones Terry C.¹²³^ORCID,Kawaoka Yoshihiro¹²¹⁴¹⁵¹⁶^ORCID,Krammer Florian¹⁷¹⁸^ORCID,McDanal Charlene⁴^ORCID,Pajon Rolando¹⁹^ORCID,Simon Viviana¹⁷¹⁸²⁰²¹^ORCID,Stockwell Melissa S.²²^ORCID,Tang Haili⁴,van Bakel Harm²³^ORCID,Veguilla Vic⁹^ORCID,Webby Richard²⁴^ORCID,Montefiori David C.⁴⁵^ORCID,Smith Derek J.¹^ORCID

Affiliation:

1. Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.

2. Institute of Virology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.

3. German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany.

4. Department of Surgery, Duke University School of Medicine, Durham, NC, USA.

5. Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.

6. Department of Global Pediatric Medicine, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN, USA.

7. Hospital Nacional Daniel A. Carrión, Callao, Bellavista, Peru.

8. Department of Pathology, Duke University School of Medicine, Durham, NC, USA.

9. Centers for Disease Control and Prevention, Atlanta, GA, USA.

10. Erasmus Medical Center, Rotterdam, Netherlands.

11. School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru.

12. Influenza Research Institute, Department of Pathobiological Science, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.

13. BC Centre for Disease Control, Vancouver, British Columbia, Canada.

14. Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

15. The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.

16. Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), University of Tokyo, Tokyo, Japan.

17. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

18. Department of Pathology, Cellular and Molecular Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

19. Moderna, Inc., Cambridge, MA, USA.

20. Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

21. The Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

22. Division of Child and Adolescent Health, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, and Department of Population and Family Health, Mailman School of Public Health, New York, NY, USA.

23. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

24. Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN, USA.

Abstract

During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, multiple variants escaping preexisting immunity emerged, causing reinfections of previously exposed individuals. Here, we used antigenic cartography to analyze patterns of cross-reactivity among 21 variants and 15 groups of human sera obtained after primary infection with 10 different variants or after messenger RNA (mRNA)–1273 or mRNA-1273.351 vaccination. We found antigenic differences among pre-Omicron variants caused by substitutions at spike-protein positions 417, 452, 484, and 501. Quantifying changes in response breadth over time and with additional vaccine doses, our results show the largest increase between 4 weeks and >3 months after a second dose. We found changes in immunodominance of different spike regions, depending on the variant an individual was first exposed to, with implications for variant risk assessment and vaccine-strain selection.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

https://www.science.org/doi/pdf/10.1126/science.adj0070

Reference74 articles.

1. World Health Organization Weekly epidemiological update on COVID-19 - 25 May 2023; https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---25-may-2023.

2. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

3. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

4. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

5. World Health Organization “Tracking SARS-CoV-2 variants ” last updated 17 August 2023; https://www.who.int/en/activities/tracking-SARS-CoV-2-variants.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, immunogenicity and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine;hLife;2024-02

2. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023;Eurosurveillance;2024-01-11

3. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera;2023-12-19

4. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities;Science Bulletin;2023-12

5. Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants;The Lancet Infectious Diseases;2023-12